IDEXX Laboratories reported strong financial results for the fourth quarter of 2024, with revenues of $954.3 million, a 6% year-over-year increase, and adjusted earnings per share (EPS) of $2.62, up 10% on a comparable basis. The company also posted net income of $216.15 million. Key growth drivers included a 7% organic increase in Companion Animal Group (CAG) Diagnostics, a 12% rise in IDEXX VetLab consumables, and a 9% organic growth in the Water segment. Pre-market trading saw IDEXX shares rise by 3%, with the stock ultimately surging 10.3% following the earnings announcement. IDEXX also allocated $249 million to repurchase 564,000 shares in Q4, contributing to a total of $859 million in share buybacks for the year. The company issued guidance for Q1 2025, projecting 4% to 6% organic revenue growth. Additionally, IDEXX announced the initial launch of its CancerDx panel for canine lymphoma detection, with plans to expand the panel to cover six prevalent canine cancers over the next three years.